Treatment of anemia in cancer patients undergoing chemotherapy with intravenous ferric carboxymaltose without erythropoiesis-stimulating agents.

Hikmat Abdel-Razeq Salwa S SaadahRazan MalhisSameer YasserHazem AbdulelahRana EljaberAmer KleibRouba Ismael

Published in: Therapeutic advances in medical oncology (2020)

Intravenous FCM is a safe and effective treatment option for the management of a subgroup of patients with CIA.The study was registered at ClinicalTrials.gov [Identifier: NCT04246021].

Keyphrases

patients undergoing
iron deficiency
high dose
chronic kidney disease
squamous cell carcinoma
randomized controlled trial
radiation therapy
papillary thyroid
low dose
young adults
childhood cancer
chemotherapy induced